MOR(Delisted)
MorphoSysยทNASDAQ
--
--(--)
MOR Profile
Morphosys Ag
A commercial-stage biopharmaceutical company that developing innovative cancer medicines
--
03/03/1998
04/19/2018
NASDAQ Stock Exchange
524
12-31
Depository Receipts (Ordinary Shares)
Semmelweisstrasse 7, 82152 Planegg, Germany
--
MorphoSys AG, founded on March 3, 1998, is a global biotechnology company focused on the development and commercialization of innovative cancer drugs. Based on its proprietary technology platform and leadership in therapeutic antibody discovery, power generation and engineering, the company is involved in the development of more than 100 therapeutic products with its partners. The company's extensive pipeline spans two business segments: proprietary development and collaborative discovery, and the company generates product candidates for its partners in the pharmaceutical and biotechnology industries based on the goals identified by the partners. The company currently has 28 product candidates in clinical development, including the state-of-the-art patented product candidate MOR208, for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
